Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Read More
Neil Desai, PhD
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review
Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa

Comments

Comments are closed.